<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:18:38Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/33790" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/33790</identifier><datestamp>2026-10-15T07:10:53Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Ghosh, Raja</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Ingawale, Mrunal Rajendra</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department">Chemical Engineering</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2026-10-14T13:41:53Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2026</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/11375/33790</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/25560</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract">Biopharmaceutical industry is evolving rapidly with development of biotherapeutic modalities. The approval of some of these products has already demonstrated their potential in the diverse domains such as oncology therapy, gene and cell therapy, vaccines. The large
modalities encompass wide range of products such as monoclonal antibodies and related products, gene therapy products, mRNA modalities, virus like particles that are significantly larger than classical therapeutics. However, there are some challenges related
to their manufacturing in terms of high dosage, purity and efficiency. Low efficiency in purification of large biotherapeutics largely arises due to steric hindrance, slow mass transfer kinetics, and shear sensitivity. Advancement in column design and purification techniques is one of the key approaches to improve the efficiency of purification processes.
Focused on developing and improving chromatography and ultrafiltration processes for purification of large biotherapeutics, this thesis revolves around different aspects of downstream processing of innovative biologics. It describes combining different separation mechanisms in terms of mixed mode chromatography approach using a z2 cuboid device for purification of monoclonal antibody
as a scalable, efficient method for removal of monoclonal antibody aggregates. It also describes key role of chromatography column design in efficiency of purification process followed by a generic and faster approach of using size exclusion chromatography (SEC)
with z2 cuboid device for separation of monoclonal antibody aggregates from monomers. Furthermore, the same chromatography device demonstrated better resolution at higher process flow rates and sample volumes. Due to the higher efficiency the SEC with z2 cuboid
device, the process was paired with membrane chromatography for complete purification of vaccine candidate SARS COV 2 spike protein. Moreover, the thesis reports the development of continuous size exclusion chromatography process named alternating flow SEC for purification of SARS CoV 2 spike protein which significantly improved
productivity of regular SEC. Beyond size exclusion chromatography, the thesis addresses some limitations of classic ultrafiltration techniques such as degradation of product, scalability and dedicated setup. A novel carrier phase ultrafiltration and backflow recovery was developed for purification of large biologics which facilitated online monitoring and
controlled concentration polarization. Through optimization study of volumetric flux, sample volume and carrier phase composition substantial improvement in process efficiency was achieved. The carrier phase ultrafiltration and backflow recovery technique was scaled up and applied for purification as well as concentration enrichment of SARS CoV 2 virus like particles (VLPs) displaying full length spike protein on their surface. The ultrafiltration step was associated with size exclusion chromatography step to achieve better purity of VLPs. It is anticipated that the contributions herein described will help address
unresolved inquiries related to large biotherapeutic purification and thus enable the development of the efficient processes at various downstream processing scales.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en_US</dim:field>
   <dim:field mdschema="dc" element="title">Innovative chromatography and ultrafiltration techniques for enhancing efficiency of large biotherapeutics purification process</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>